BioGaia (OM:BIOG B) Could Be 26% Undervalued Following Its Recordati Deal

BioGaia (OM:BIOG B) is back in focus after signing a new long term exclusive distribution agreement with Recordati for Spain and Portugal, extending their existing Iberian and Italian probiotic collaboration.

At a share price of SEK113.4, BioGaia has delivered an 8.0% year to date share price return and a 12.38% total shareholder return over the past year, while the 90 day share price performance has been weaker. This suggests momentum has cooled even as the new Iberian agreement refocuses attention on its longer term 3 year and 5 year total shareholder returns of 37.37% and 44.31%.

Scan how BioGaia compares with other healthcare stocks showing resilient growth and balance sheets using our hand picked list of solid balance sheet and fundamentals (438 results)

Bulls point to BioGaia’s global probiotic footprint and fresh Iberian deal, while bears worry recent share price softness hints at stretched expectations. Which side does the current valuation support as you weigh the next move?

Most Popular Narrative: 25.6% Undervalued

The most followed valuation narrative for BioGaia places fair value at SEK152.5 per share, compared with the latest close at SEK113.4. That gap rests on a specific set of growth and profitability assumptions that investors should understand before leaning on the story.

BioGaia's strategic shift to direct sales in new and existing markets (e.g., Netherlands, France, Australia, U.S.) leverages rising consumer demand for natural and clinically-proven solutions, paving the way for improved operating leverage and long-term margin expansion as direct business now represents 36% of sales and continues to grow.

Read the complete narrative. Read the complete narrative.

Want to understand why this valuation leans so heavily on direct sales and premium products? The narrative rests on faster revenue growth, higher margins and a richer earnings multiple than today. The exact mix of those three variables is what drives the SEK152.5 fair value.

Result: Fair Value of SEK152.5 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, BioGaia’s higher operating expenses and concentrated reliance on pediatric products could undermine the bullish narrative if earnings and diversification do not keep pace.

Find out about the key risks to this BioGaia narrative.

Next Steps

Given the mix of optimism around BioGaia and the clear concerns raised, it makes sense to review the underlying data yourself and move quickly to form your own view using the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond BioGaia?

If you are serious about building a stronger portfolio, do not stop with BioGaia. Use the Simply Wall Street Screener to uncover fresh ideas that match your style.

• Target potential bargains with quality fundamentals by reviewing companies highlighted in the 257 high quality undervalued stocks.
• Strengthen your income stream by checking stocks in the 417 dividend fortresses that pair higher yields with durable profiles.
• Prioritise capital preservation by focusing on companies in the 308 resilient stocks with low risk scores that score well on stability and resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com